Anixa Biosciences (NASDAQ:ANIX) Stock Price Up 3.2%

Anixa Biosciences, Inc. (NASDAQ:ANIXGet Rating)’s share price rose 3.2% during mid-day trading on Friday . The company traded as high as $5.04 and last traded at $4.90. Approximately 34,965 shares were traded during mid-day trading, a decline of 58% from the average daily volume of 83,798 shares. The stock had previously closed at $4.75.

Anixa Biosciences Stock Up 3.2 %

The stock has a 50 day moving average price of $5.11 and a 200 day moving average price of $4.09. The stock has a market capitalization of $150.23 million, a price-to-earnings ratio of -10.43 and a beta of 1.14.

Anixa Biosciences (NASDAQ:ANIXGet Rating) last announced its quarterly earnings results on Friday, September 9th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.04. Sell-side analysts forecast that Anixa Biosciences, Inc. will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Anixa Biosciences

Hedge funds have recently made changes to their positions in the company. US Bancorp DE boosted its stake in shares of Anixa Biosciences by 3,312.3% during the first quarter. US Bancorp DE now owns 13,649 shares of the company’s stock valued at $37,000 after purchasing an additional 13,249 shares in the last quarter. Keybank National Association OH acquired a new position in shares of Anixa Biosciences in the first quarter worth approximately $42,000. Virtu Financial LLC acquired a new position in shares of Anixa Biosciences in the second quarter worth approximately $45,000. LPL Financial LLC acquired a new position in shares of Anixa Biosciences in the second quarter worth approximately $67,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in shares of Anixa Biosciences in the third quarter worth approximately $74,000. 10.73% of the stock is owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

(Get Rating)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.

See Also

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.